Jul 31, 2025 • Zacks Commentary
NEUTRAL
Bausch Health Stock Falls on Q2 Earnings Miss, Revenues Beat
BHC stock falls 6.3% as Q2 earnings miss estimates despite stronger sales and growth in key segments like Salix and Solta Medical.
Jul 31, 2025 • Motley Fool
SOMEWHAT-BULLISH
Bausch Lomb ( BLCO ) Q2 Revenue Rises 5%
Bausch + Lomb ( NYSE:BLCO ) , a global eye health company known for its contact lenses, surgical devices, and eye pharmaceuticals, released results for the second quarter of fiscal 2025 on July 30, 2025. The main headline from the release is GAAP revenue growth of 5% year over year to $1.278 ...
Jul 30, 2025 • Zacks Commentary
NEUTRAL
Bausch + Lomb ( BLCO ) Q2 Earnings and Revenues Surpass Estimates
Bausch + Lomb (BLCO) delivered earnings and revenue surprises of +16.67% and +2.37%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Jul 30, 2025 • Zacks Commentary
SOMEWHAT-BEARISH
New Strong Sell Stocks for July 30th
ACHC, BLCO and BBCP have been added to the Zacks Rank #5 (Strong Sell) List on July 30, 2025.
Jul 29, 2025 • Benzinga
NEUTRAL
Bausch Health Buys DURECT, Adds Liver Disease Drug In $63M Deal - Durect ( NASDAQ:DRRX ) , Bausch Health Companies ( NYSE:BHC )
Bausch Health to acquire DURECT for $63 million upfront, plus up to $350 million in milestone payments. Phase 3 trial for AH drug larsucosterol to begin, with 90-day survival as primary endpoint. The market's back, and these 3 income stocks are thriving. See them here→ Bausch Health Companies ...
Jul 24, 2025 • Zacks Commentary
NEUTRAL
New Strong Sell Stocks for July 24th
COMP, EKTAY and BLCO have been added to the Zacks Rank #5 (Strong Sell) List on July 24, 2025.